Chemomab Therapeutics Ltd.: current assets
Current assets for Chemomab Therapeutics Ltd. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Chemomab Therapeutics Ltd. financial histories
What this measure means
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
Exact concept: us-gaap:AssetsCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 13,425,000 | USD | 2026-03-23 | 20-F · 0001178913-26-001593 |
| At date | 2024-12-31 | 16,040,000 | USD | 2026-03-23 | 20-F · 0001178913-26-001593 |
| At date | 2023-12-31 | 20,897,000 | USD | 2025-04-04 | 20-F · 0001178913-25-001205 |
| At date | 2022-12-31 | 41,736,000 | USD | 2024-03-28 | 20-F · 0001178913-24-001124 |
| At date | 2021-12-31 | 62,688,000 | USD | 2023-03-20 | 10-K · 0001178913-23-001041 |
| At date | 2020-12-31 | 11,839,000 | USD | 2022-03-30 | 10-K · 0001178913-22-001304 |
| At date | 2019-12-31 | 18,211,000 | USD | 2021-03-09 | 10-K · 0001104659-21-033822 |
| At date | 2018-12-31 | 10,920,000 | USD | 2020-03-17 | 10-K · 0001104659-20-034835 |
Related financial histories
- Chemomab Therapeutics Ltd.: total assets
- Chemomab Therapeutics Ltd.: total liabilities
- Chemomab Therapeutics Ltd.: stockholders equity
- Chemomab Therapeutics Ltd.: cash and cash equivalents
- Chemomab Therapeutics Ltd.: net income or loss
- Chemomab Therapeutics Ltd.: operating cash flow
- Chemomab Therapeutics Ltd.: capital expenditure payments
- Chemomab Therapeutics Ltd.: financing cash flow
- Chemomab Therapeutics Ltd.: investing cash flow
- Chemomab Therapeutics Ltd.: retained earnings or deficit
- Chemomab Therapeutics Ltd.: basic weighted-average shares
- Chemomab Therapeutics Ltd.: diluted weighted-average shares
- Chemomab Therapeutics Ltd.: basic earnings per share
- Chemomab Therapeutics Ltd.: diluted earnings per share
- Chemomab Therapeutics Ltd.: income tax expense or benefit
- Chemomab Therapeutics Ltd.: net property, plant and equipment
- Chemomab Therapeutics Ltd.: share-based compensation expense
- Chemomab Therapeutics Ltd.: current liabilities
- Chemomab Therapeutics Ltd.: operating expenses
- Chemomab Therapeutics Ltd.: cost of revenue
- Chemomab Therapeutics Ltd.: research and development expense
Inspect the source
- Entity
- Chemomab Therapeutics Ltd. / CIK 0001534248
- Captured
- 2026-09-20T09:16:39.466Z
- SEC response SHA-256
737f2c1429e733f20983ab524655c974f3445e8d5fe0e9cdf24c1175086ec27a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001534248.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))